UBS is also launching deals this week for Leiner Health Products and Sterigenics International. The Leiner facility, led by UBS, Morgan Stanley and Credit Suisse First Boston, is made up of a five-year, $50 million revolver and seven-year, $240 million term loan. The Sterigenics deal comprises a $35 million revolver, $170.5 million term loan and $35 million second-lien term loan. Price talk on the first- and second-lien term loans is LIBOR plus 3% and 6 1/4%, respectively. Ballpark pricing on the revolver was not available. The Leiner credit backs a $650 million recapitalization of the vitamin maker by North Castle Partners and Golden Gate Capital. The Sterigenics deal backs PPM Ventures' and PPM America Capital Partners' acquisition of the sterilization and ionization business of Ion Beam Applications. A PPM official declined comment.
Promoted By CGIF
Promoted By Commerzbank
Want full access to GlobalCapital?
If you are new to GlobalCapital or you already subscribe to some of our channels you can still easily extend your access.
Take a trial to the entire site or subscribe online to see all our capital markets news, opinion and data sets.
Don't miss out!Free trial
Read the magazine on your mobile device
Most Viewed: Securitization
Latest news by market and league table performance
|Rank||Lead Manager/Arranger||Total Volume $m||No. of Deals||Share % by Volume|
|1||Bank of America Merrill Lynch (BAML)||7,026||25||11.95|
Bookrunners of Global Structured Finance
|Rank||Lead Manager||Amount $m||No of issues||Share %|
|2||SG Corporate & Investment Banking||1,292.64||1||17.91%|
|4||Wells Fargo Securities||760.56||2||10.54%|